AD生物标志物可以预测认知损害.pdfVIP

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later Catherine M. Roe, PhD ABSTRACT Anne M. Fagan, PhD Objectives: We compared the ability of molecular biomarkers for Alzheimer disease (AD), including Elizabeth A. Grant, PhD amyloid imaging and CSF biomarkers (Ab42, tau, ptau181, tau/Ab42, ptau181/A b42), to predict Jason Hassenstab, PhD time to incident cognitive impairment among cognitively normal adults aged 45 to 88 years and Krista L. Moulder, PhD followed for up to 7.5 years. Denise Maue Dreyfus, Methods: Longitudinal data from Knight Alzheimer’s Disease Research Center participants (N 5 MA 201) followed for a mean of 3.70 years (SD 5 1.46 years) were used. Participants with amyloid Courtney L. Sutphen, BS imaging and CSF collection within 1 year of a clinical assessment indicating normal cognition Tammie L.S. Benzinger, were eligible. Cox proportional hazards models tested whether the individual biomarkers were MD related to time to incident cognitive impairment. “ Expanded” models were developed using the Mark A. Mintun, MD biomarkers and participant demographic variables. The predictive values of the models were David M. Holtzman, MD compared. John C. Morris, MD Results: Abnormal levels of all biomarkers were associated with faster time to cognitive impair- ment, and some participants with abnormal biomarker levels remained cognitively normal for up Correspondence to to 6.6 years. No differences in predictive value were found between the